Capital World Investors’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $191M | Buy |
5,209,427
+5,010,064
| +2,513% | +$237M | 0.03% | 315 |
|
|
2025
Q4 | $10.2M | Sell |
199,363
-11,499
| -5% | -$588K | ﹤0.01% | 507 |
|
|
2025
Q3 | $11.7M | Sell |
210,862
-4,824
| -2% | -$282K | ﹤0.01% | 499 |
|
|
2025
Q2 | $14.8M | Buy |
215,686
+7,916
| +4% | +$538K | ﹤0.01% | 486 |
|
|
2025
Q1 | $14.4M | Sell |
207,770
-4,238,249
| -95% | -$350M | ﹤0.01% | 472 |
|
|
2024
Q4 | $382M | Sell |
4,446,019
-7,997
| -0.2% | -$865K | 0.06% | 215 |
|
|
2024
Q3 | $531M | Sell |
4,454,016
-9,869
| -0.2% | -$1.32M | 0.08% | 183 |
|
|
2024
Q2 | $638M | Buy |
4,463,885
+535,463
| +14% | +$71M | 0.1% | 164 |
|
|
2024
Q1 | $504M | Sell |
3,928,422
-42,995
| -1% | -$5.12M | 0.08% | 198 |
|
|
2023
Q4 | $411M | Buy |
3,971,417
+5,059
| +0.1% | +$500K | 0.07% | 217 |
|
|
2023
Q3 | $361M | Buy |
3,966,358
+2,356
| +0.1% | +$208K | 0.07% | 226 |
|
|
2023
Q2 | $320M | Buy |
3,964,002
+458,288
| +13% | +$37.4M | 0.06% | 233 |
|
|
2023
Q1 | $279M | Buy |
3,505,714
+707,540
| +25% | +$50.2M | 0.06% | 251 |
|
|
2022
Q4 | $189M | Buy |
2,798,174
+1,339,910
| +92% | +$78.6M | 0.04% | 282 |
|
|
2022
Q3 | $72.7M | Buy |
1,458,264
+1,385,042
| +1,892% | +$74.2M | 0.02% | 361 |
|
|
2022
Q2 | $4.03M | Buy |
73,222
+1,300
| +2% | +$72.1K | ﹤0.01% | 510 |
|
|
2022
Q1 | $4.05M | Buy |
71,922
+4,478
| +7% | +$230K | ﹤0.01% | 540 |
|
|
2021
Q4 | $3.76M | Buy |
67,444
+5,632
| +9% | +$305K | ﹤0.01% | 577 |
|
|
2021
Q3 | $2.97M | Buy |
61,812
+1,690
| +3% | +$81.7K | ﹤0.01% | 587 |
|
|
2021
Q2 | $2.52M | Buy |
60,122
+4,520
| +8% | +$175K | ﹤0.01% | 586 |
|
|
2021
Q1 | $1.89M | Buy |
55,602
+9,188
| +20% | +$327K | ﹤0.01% | 571 |
|
|
2020
Q4 | $1.63M | Buy |
46,414
+6,462
| +16% | +$223K | ﹤0.01% | 550 |
|
|
2020
Q3 | $1.4M | Buy |
39,952
+2,238
| +6% | +$74.6K | ﹤0.01% | 542 |
|
|
2020
Q2 | $1.24M | Buy |
37,714
+12,310
| +48% | +$393K | ﹤0.01% | 511 |
|
|
2020
Q1 | $764K | Buy |
25,404
+7,860
| +45% | +$234K | ﹤0.01% | 496 |
|
|
2019
Q4 | $506K | Buy |
17,544
+3,910
| +29% | +$108K | ﹤0.01% | 501 |
|
|
2019
Q3 | $352K | Buy |
13,634
+13,158
| +2,764% | +$333K | ﹤0.01% | 517 |
|
|
2019
Q2 | $12K | Buy |
476
+454
| +2,064% | +$11.2K | ﹤0.01% | 530 |
|
|
2019
Q1 | $1K | Hold |
22
| – | – | ﹤0.01% | 523 |
|
|
2018
Q4 | $1K | Hold |
22
| – | – | ﹤0.01% | 519 |
|
|
2018
Q3 | $1K | Buy |
+22
| New | +$537 | ﹤0.01% | 546 |
|
|
2018
Q2 | – | Sell |
-12
| Closed | – | – | 554 |
|
|
2018
Q1 | $0 | Buy |
+12
| New | +$315 | ﹤0.01% | 539 |
|
|
2017
Q4 | – | Sell |
-10
| Closed | – | – | 519 |
|
|
2017
Q3 | $0 | Buy |
+10
| New | +$226 | ﹤0.01% | 513 |
|
Other funds holding NVO
DAM
F
Capital World Investors's NVO Position: Q1 2026 in Review
Capital World Investors increased its Novo Nordisk (NVO) stake by 2,513% in Q1 2026, buying an estimated $237M and bringing the position to 5,209,427 shares worth $191M. The position accounts for 0.03% of the portfolio, ranked #315.
Capital World Investors first reported a position in NVO in Q3 2017 and has held it in 33 quarters since. The position peaked at $638M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.
- Capital World Investors held 5,209,427 shares of Novo Nordisk worth $191M as of Q1 2026.
- Capital World Investors bought 5,010,064 Novo Nordisk shares in Q1 2026, an estimated $237M.
- Novo Nordisk made up 0.03% of Capital World Investors's portfolio in Q1 2026, its #315 holding.
- Capital World Investors first reported a position in Novo Nordisk in Q3 2017 and has held it in 33 quarters since.
- Capital World Investors's Novo Nordisk position peaked at $638M in Q2 2024.
- 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.
Based on Capital World Investors's 13F filing for Q1 2026, filed 13 May 2026.